Alpha-glucosidase inhibitors work by blocking the intestinal brush-border enzymes that break down complex carbohydrates into absorbable glucose. By inhibiting these enzymes, carbohydrate digestion is slowed, delaying glucose absorption and blunting the post-meal rise in blood glucose. This effect is localized to the gut and does not stimulate insulin release, increase hepatic glucose production, or cause renal glucose excretion. GI side effects from undigested carbohydrates reaching the colon are common, such as gas and diarrhea.

Understanding A1c thresholds and what they mean for glucose status is the key idea here. Prediabetes is defined by an A1c in the 5.7% to 6.4% range. An A1c of 5.9% falls right within that range, so it indicates prediabetes rather than normal glucose tolerance or diabetes. Symptoms are not required for this classification; the lab value itself places someone in the prediabetes category. In practice, clinicians may repeat testing or use additional measures to confirm the overall glucose status, but the A1c level of 5.9% already identifies prediabetes.

Canagliflozin is an SGLT2 inhibitor, so when thinking about drug interactions the focus is on effects that change its exposure or increase risks from diuresis. Diuretics can heighten the risk of volume depletion and low blood pressure when used with canagliflozin because both promote fluid loss. In addition, drugs that induce hepatic enzymes or transporters—like rifampin, phenytoin, and phenobarbital—can increase the metabolism of canagliflozin, lowering its levels and potentially reducing its glucose-lowering effect. That combination—diuretics plus enzyme inducers—best captures the known interactions with canagliflozin. The other options don’t reflect meaningful pharmacokinetic interactions with canagliflozin. ACE inhibitors and ARBs are commonly used with canagliflozin and mainly require monitoring for blood pressure and kidney function rather than a direct drug–drug interaction. Metformin and glyburide can be used together with canagliflozin without a specific interaction that changes its exposure. Acetaminophen and ibuprofen do not affect canagliflozin’s pharmacokinetics.

The brain relies almost entirely on glucose for its energy. When blood glucose drops, brain cells can’t generate enough energy to function, leading to neuroglycopenia where brain activity falters. This energy shortage quickly affects consciousness and vital brain functions, and if hypoglycemia isn’t corrected promptly, it can progress to seizures, coma, and potentially death. That’s why the statement about the brain not having glucose for basic functions describes the fatal consequence of hypoglycemia. The other options describe effects that don’t reflect the brain-energy crisis caused by low glucose.